|
KMID : 1123920060200061678
|
|
Korean Journal of Oriental Physiology and Pathology
2006 Volume.20 No. 6 p.1678 ~ p.1727
|
|
|
Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products
|
|
Kim Sung-Hoon
Namgung Mi-Ae
Chang Yoo-Sung
Jeong Seung-Ki
Kim Jin-Seung
Yoon Sung-Woo
Jang Ki-Young
Yoo Hwa-Seung
Chung Myeon-Woo
Lee Sung-Ho
|
|
|
Abstract
|
|
|
|
This study was perfromed to develop the assessment guideline and endpoints for clinical trial with anticancer herbal medicine. The botanical products used to humans for long time may be applied to phase 3 clinical trial after submitting the evidences for safety and efficacy of them or completion of basic requirement of phase 1 and phase 2 for safety confirmation and dose determination. Syndrome improvement was chiefly evaluated by Zubrod and karnofsky(%) methods. We suggest the general clinical trial assessment with botanical products, by following assessment points, that is, tumor size for 50 points, survival fate for 10 points, major syndromes for 40 points. It is recommendable that the each symptom of Qi deficiency syndrome, blood deficiency syndrome and Qi stagnation syndrome was allocated by assessment points, Similarly, the each symptom was given the assessment points according to the severity of symptom, for example, slight for 3 points, moderate for 2 points and severe for 1 point in hepatocelluar carcinoma and lung cancer. Then, the efficacy of botanical products was evaluated by the difference between pre-treatment and post-treatment. Asking the neoplastic patients of questionnaire on physical, emotional, cognitive, social and role subjects availability, three more syndromes (Fatigue, Pain and Nausea/Vomit), quality of life(QOL) will be evaluated by GLM statistics. In addition, in case of lung cancer, 13 questions will be asked by the EORTC QLQ-C13 forms. As the assessment of endpoints for efficacy to reduce side effects induced by chemotherapy and radiotherapy, the data of image scanning and hemato-urinalysis can be usefully applied on immune response, weight loss, indigestion, hemopoietic damage and injury of liver and kidney, while the changes of syndromes of side effect can be evaluated by differentiation methods of Qi and blood and five viscera. However, it is still necessary to determine the ratio between scientific analytical method and Oriental differentiation method as well as confirm the Oriental assessment endpoints by clinical trial. In addition, we suggest the continuous development of assessment endpoints on other carcinomas except of hepatocelluar carcinoma and lung cancer in future.
|
|
|
KEYWORD
|
|
|
Clinical Trial, Endpoints, Antitumor Natural Products, QOL
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|